to CAR T-cell therapy is of major clinical importance. Abnormal skeletal muscle measurements at baseline such as low muscle mass and resultant fat infiltration (myosteatosis) have been associated with adverse cancer-related outcomes and all
Search Results
Kyuwan Lee, Aleksi Iukuridze, Tianhui He, Alysia Bosworth, Lanie Lindenfeld, Jennifer Berano Teh, Meagan Echevarria, Sophia Albanese, Liezl Atencio, Rusha Bhandari, F. Lennie Wong, Andrew S. Artz, Tanya Siddiqi, Liana Nikolaenko, Jasmine Zain, Matthew Mei, Geoffrey Shouse, Leslie L. Popplewell, Alex F. Herrera, L. Elizabeth Budde, Stephen J. Forman, and Saro H. Armenian
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Christos S. Karapetis, Ashley M. Hopkins, and Michael J. Sorich
associated with several adverse outcomes, including increased all-cause mortality, cardiovascular and renal diseases, dementia, infections, fractures, hypomagnesemia, and cancers. 2 , 3 In contrast, in preclinical in vitro studies, PPIs were initially
Andrew K. Lee and Christopher L. Amling
F or decades physicians have attempted to accurately predict post-treatment outcomes before performing prostate cancer interventions. Use of basic clinical factors, such as clinical T-stage, biopsy Gleason sum, and pretreatment prostate
Julie A. Wolfson, Kelly M. Kenzik, Blake Foxworthy, John M. Salsman, Katherine Donahue, Marie Nelson, Mary Beth Littrell, Grant R. Williams, and Jennifer M. Levine
the AYA cancer population, some regions have seen improvements despite persistence of disparities as a whole 10 ; this suggests that as we strive toward additional improvements, it is critical to continue to consider AYA outcomes in the context of
Hermioni L. Amonoo, Elizabeth Daskalakis, Emma C. Deary, Monica H. Bodd, Matthew J. Reynolds, Ashley M. Nelson, Richard Newcomb, Tejaswini M. Dhawale, Daniel Yang, Selina M. Luger, Jillian L. Gustin, Andrew Brunner, Amir T. Fathi, Thomas W. LeBlanc, and Areej El-Jawahri
outcomes based on a given context) relies on the availability and utilization of a variety of coping strategies. 16 Although we know that patients with newly diagnosed AML use a variety of coping strategies both in the avoidant and approach-oriented coping
Mikkael A. Sekeres
.S. Interim projections by age, sex, race, and Hispanic origin . Available at : http://www.census.gov/ipc/www/usinterimproj . Accessed October 19, 2005 . 9. Friedberg JW Neuberg D Stone RM . Outcome in patients with myelodysplastic syndrome
Eva Battaglini, David Goldstein, Peter Grimison, Susan McCullough, Phil Mendoza-Jones, and Susanna B. Park
moderate recommendation in the ASCO guidelines, 21 , 22 was reported by 1.5% (n=15) of respondents. Long-Term Outcomes in Survivors With Severe Neurotoxicity Comparing respondents reporting high (upper-tertile FACT/GOG-NTX) versus low (lowest-tertile FACT
Rodger J. Winn
. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines . J Clin Oncol 1996 ; 14 : 671 – 679 . 3 Nease RF Kneeland T O'Connor GT . Variation in patient utilities for outcomes of the management of chronic stable
Ryan D. Nipp, Leah L. Thompson, Brandon Temel, Charn-Xin Fuh, Christine Server, Paul S. Kay, Sophia Landay, Daniel E. Lage, Lara Traeger, Erin Scott, Vicki A. Jackson, Nora K. Horick, Joseph A. Greer, Areej El-Jawahri, and Jennifer S. Temel
adults with cancer who may experience poor outcomes. Although older patients with cancer represent an increasing and heterogeneous population with diverse needs, little research has sought to identify those at risk of experiencing high symptom burden or
Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp
symptom burden and other clinical outcomes. Notably, hospitalized patients with cancer may actually experience more severe symptom burden and functional decline than those in the outpatient setting. 3 These patients are also at risk for poor clinical
